Cyteir Therapeutics, Inc.(NASDAQ : CYT)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Commercial Services » Miscellaneous Commercial Services
|TAL||TAL Education Group||3.41%||6.07||0.7%||$335.89m|
|BTBT||Bit Digital, Inc.||13.07%||9.00||0.0%||$207.24m|
|FLT||FLEETCOR Technologies, Inc.||-0.73%||258.08||3.6%||$176.65m|
|PAGS||PagSeguro Digital Ltd.||-2.17%||55.41||0.0%||$112.88m|
|CRL||Charles River Laboratories International, Inc.||0.21%||406.37||4.5%||$103.83m|
|FOUR||Shift4 Payments, Inc.||-1.10%||89.19||0.0%||$97.85m|
|BR||Broadridge Financial Solutions, Inc.||0.54%||173.40||1.5%||$75.21m|
|SYNH||Syneos Health, Inc.||0.25%||89.67||0.0%||$58.10m|
Cyteir Therapeutics, Inc. engages in the development of novel therapeutics and deoxyribonucleic acid repair and synthetic lethal therapies. It exploits the synthetic lethality of gain-of-function DNA-damaging genes and DNA repair inhibition, resulting in selective death among cells. The company was founded by Kevin Mills and Timothy Romberger in June 2012 and is headquartered in Lexington, MA.